Surface oncology, inc. (SURF)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Collaboration revenue - related party

38,592

439

344

143

14,434

9,764

1,730

2,428

45,495

-

-

-

-

Collaboration revenue - related party

-

-

-

-

-

-

-

-

-

-

2,480

6,195

1,672

Operating expenses:
Research and development

11,288

11,657

12,916

13,236

14,309

10,521

15,783

15,098

11,090

16,282

12,101

10,720

8,680

General and administrative

4,787

5,114

4,984

5,417

5,093

4,824

3,977

3,913

3,362

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

4,651

2,004

1,546

Total operating expenses

16,075

16,771

17,900

18,653

19,402

15,345

19,760

19,011

14,452

19,114

16,752

12,724

10,226

Income (loss) from operations

22,517

-16,332

-17,556

-18,510

-4,968

-5,581

-18,030

-16,583

31,043

-16,635

-14,272

-6,529

-8,554

Interest and other income, net

53

378

678

752

769

846

808

731

169

143

208

120

142

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-14,064

-6,409

-8,412

Provision for income taxes

-

-

-

-

-

-

-

-

-

-

341

164

214

Net income (loss)

22,570

-15,954

-16,878

-17,758

-4,199

-4,735

-17,222

-15,852

31,212

-15,773

-14,405

-6,573

-8,626

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

0

0

0

11

-

-

-

-

Net income attributable to redeemable convertible preferred stockholders

-

-

-

-

-

-

-

-19,789

26,866

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

10

10

10

Net loss attributable to common stockholders

-

-

-16,878

-17,758

-

22,131

-17,222

-15,852

4,335

-

-14,415

-

-

Net loss per share attributable to common stockholders—basic and diluted

-

-

-0.61

-

-

-

-0.62

-

-

-

-5.75

-

-

Net (loss) income attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-6,583

-8,636

Net income (loss) per share attributable to common stockholders— basic

0.81

-

-

-0.64

-0.15

-

-

-0.73

1.59

-

-

-2.73

-3.60

Weighted average common shares outstanding— basic

27,977

-

-

27,845

27,825

-

-

21,595

2,727

-

-

2,413

-

Weighted average common shares outstanding—basic and diluted

-

-

27,862

-

-

-

27,598

-

-

-

2,506

-

2,399

Net income (loss) per share attributable to common stockholders— diluted

0.74

-

-

-0.64

-0.15

-

-

-0.73

1.05

-

-

-2.73

-3.60

Weighted average common shares outstanding— diluted

30,917

-

-

27,845

27,825

-

-

21,595

4,134

-

-

2,413

2,399

Comprehensive income (loss):
Net income (loss)

22,570

-15,954

-16,878

-17,758

-4,199

-4,735

-17,222

-15,852

31,212

-15,773

-14,405

-6,573

-8,626

Other comprehensive income (loss):
Unrealized gain on marketable securities, net of tax of $0

67

-35

-36

169

124

71

43

63

-50

-

-

-

-

Unrealized gain on marketable securities, net of tax of $0

-

-

-

-

-

-

-

-

-

-

43

40

93

Comprehensive income (loss)

22,637

-15,989

-16,914

-17,589

-4,075

-4,664

-17,179

-15,789

31,162

-15,842

-14,362

-6,533

-8,533